Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Genómica personalizada para la detección de anomalías prenatales utilizando sangre materna (PEGASUS-2)

12 de noviembre de 2026 actualizado por: François Rousseau, CHU de Quebec-Universite Laval

Genómica personalizada para la detección de anomalías prenatales utilizando sangre materna: hacia la detección de primer nivel y más allá

This project aims to provide high- quality evidence to inform decisions by health care organisations about using first-tier non-invasive prenatal screening (NIPS) to replace traditional screening tests for trisomy 21, and potentially to screen for other fetal chromosome anomalies. We will compare the current screening approach of second-tier NIPS with the use of first-tier NIPS in a large cohort of pregnant women.

Descripción general del estudio

Descripción detallada

There is some data on the performance of NIPS as a first tier screening test but our systematic review has shown that no trial comparing the effectiveness (utility) of 2nd-tier NIPS with that of first-tier NIPS has been published . Further it is important for health care decision makers to have evidence produced in Canada since the geographical context of healthcare can affect uptake as well as patient decision and thus their healthcare trajectories. There is a need for a trial that is between an explanatory trial and a pragmatic trial to provide the types of answer that we aim to document in the present state of knowledge on NIPS-based screening strategies in Canada. Our Objective is to perform a pan-Canadian large-scale comparative utility (clinical outcomes) study of first-tier NIPS (expanded or not) as compared to the new standard of care (NIPS as a 2nd tier test performed much later during pregnancy and only in high risk pregnancies).

Tipo de estudio

Intervencionista

Inscripción (Actual)

7849

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • British Columbia
      • Kelowna, British Columbia, Canadá, V1Y 1P2
        • Kelowna Regional Fertility Center
      • Prince Rupert, British Columbia, Canadá, V8J 2A6
        • Prince Rupert Regional Hospital
      • Vancouver, British Columbia, Canadá, V6H 3N1
        • Children's & Women's Health Centre
    • Quebec
      • Montreal, Quebec, Canadá, H3T 1C5
        • CHU Ste-Justine
      • Québec, Quebec, Canadá, G1L3L5
        • CHU de Québec - Université Laval
      • Sept-Îles, Quebec, Canadá, G4R 0N9
        • CIUSSS Côte-Nord

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Pregnant women 19 years or older wanting prenatal screening
  • 10-13+6 wks determined by dating ultrasound or last menstrual period.
  • Not intending to pursue self pay NIPT

Exclusion Criteria:

  • Known fetal anomaly at the time of recruitment
  • Multiple gestation
  • Known twin demise
  • Planned CVS or amnio for known genetic condition.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Poner en pantalla
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Standard of care (2nd tier NIPS)

For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).

biochemical prenatal screening with or without nuchal translucency by US

Otros nombres:
  • IPS

genomics based NIPS after a positive traditional prenatal screen

Otros nombres:
  • pruebas prenatales no invasivas de segundo nivel (NIPT)

amniocentesis or chorionic villi sampling (CVS)

Experimental: First-tier NIPS

For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).

amniocentesis or chorionic villi sampling (CVS)

genomics based NIPS at first trimester

Otros nombres:
  • NIPT de primer nivel, NIPS universal, NIPT universal

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gestational age at diagnosis
Periodo de tiempo: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a positive NIPS result and that have been offered diagnostic testing

Up to 24 weeks of gestational age

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gestational age at negative screening result
Periodo de tiempo: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a negative screening result

Up to 24 weeks of gestational age
Gestational age at positive screening result
Periodo de tiempo: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a positive screening result

Up to 24 weeks of gestational age
proportion of women with no results
Periodo de tiempo: Up to 24 weeks of gestational age

proportion of women with no NIPS result at first and second attempt

Up to 24 weeks of gestational age
numbers of days for women with false positive result of screen to wait for result of definite test
Periodo de tiempo: Up to 24 weeks of gestational age

Difference between gestational age (in days) at first positive prenatal screening result and final negative screening result

Up to 24 weeks of gestational age
Change in PROMIS-29 Score
Periodo de tiempo: At weeks of gestation 10-13, week 16 and week 22

The PROMIS-29 assesses seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to participate in social roles and activities. Each of the seven domains has four questions which are scored on a five-point Likert scale. The PROMIS-29 scales will be scored using a T-score metric method available at the Assessment Center website (http://assessmentcenter.net). A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean more of the specific scale's construct, which may indicate a desirable or an undesirable outcome. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation.

At weeks of gestation 10-13, week 16 and week 22
Change in PROMIS Emotional Distress - Anxiety - Short Form 8a Score
Periodo de tiempo: At weeks of gestation 10-13, 16 and 22

The PROMIS-Anxiety short form assesses anxiety with 8 questions. The form includes 8 items and uses a scale of 1-5 (1=Never, 2=Almost never, 3= Sometimes, 4=Often, 5=Almost always). The raw score is the sum of the points for each response. A higher than average raw score indicates higher than average anxiety. A higher score represents higher levels of anxiety. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation.

At weeks of gestation 10-13, 16 and 22
Patient-Reported Experience Measure (PREM) - Score
Periodo de tiempo: At 22 weeks of gestation

A 17-questions validated PREM questionnaire on pregnancy experience that measures three dimensions - type of prenatal care received and test results (seven questions), pregnancy visits (four questions (scales 1-5) and prenatal screening experience (six questions).

A profile score by looking at frequencies of responses for each item will be used.

At 22 weeks of gestation
gestational age at termination of pregnancy
Periodo de tiempo: Up to 24 weeks of gestational age

Gestational age at termination of pregnancy for participants having volountary termination

Up to 24 weeks of gestational age
percentage of women undergoing invasive diagnostic testing
Periodo de tiempo: Up to 24 weeks of gestational age

see outcome title

Up to 24 weeks of gestational age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Sylvie Langlois, MD FRCPC, University of British Columbia
  • Investigador principal: Francois Rousseau, MD MSc FRCPC, CHU de Québec - Université Laval

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

13 de enero de 2020

Finalización primaria (Actual)

30 de septiembre de 2024

Finalización del estudio (Actual)

30 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

21 de enero de 2019

Primero enviado que cumplió con los criterios de control de calidad

4 de febrero de 2019

Publicado por primera vez (Actual)

5 de febrero de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir